Besifloxacin nanostructured lipid carrier containing for the treatment ophthalmic infections: preparation, physicochemical and biological characterization in vitro and in vivo (2023)
- Authors:
- Autor USP: HENOSTROZA, MIRLA ANALI BAZAN - FCF
- Unidade: FCF
- Sigla do Departamento: FBF
- DOI: 10.11606/T.9.2023.tde-08032024-162552
- Assunto: ESTABILIDADE
- Keywords: Atividade antimicrobiana in vitro; Besifloxacin; Besifloxacino; Carreador lipídico nanoestruturado (CLN); Citotoxicidade; Cytotoxicity; Estabilidade; In vitro antimicrobial activity; Nanostructured lipid carrier (NLC); Stability
- Agências de fomento:
- Language: Inglês
- Abstract: Conjunctivitis, keratitis, and blepharitis are the most frequent ophthalmic infections caused mainly by bacteria. Conventional treatment consists of topical administration of broad-spectrum antibiotics. Due to ocular barriers, topical treatment requires high doses and repeated administrations to achieve a therapeutic effect. Besifloxacin, a new generation of fluoroquinolone, indicated exclusively for the topical treatment of ophthalmic infections, has low solubility in water. This characteristic limit its bioavailability and predisposes it to the development of resistance. Thus, innovative approaches are needed in the development of antibiotic containing eye drops. Nanostructured lipid carrier (NLC) may present innovative properties attributed to the nanometric scale. This project's objective was to prepare and evaluate the physicochemical and biological characteristics of NLC containing besifloxacin (BFX-NLC) for ophthalmic use. Solid and liquid lipid selection was carried out using the saturation method. NLCs were prepared by the high-pressure homogenization method. BFX showed higher solubility in capric/caprylic acid triglycerides and Softisan®154 among the liquid and solid lipids tested. The optimized BFX-NLC showed Z-aveof 93.6 ± 1.7 nm and a polydispersion index (PDI) equal to 0.15 ± 1.7. The physical stability showed no change in Z-ave and IP for nine months, at 30 ± 2 °C and 75 ± 5 % relative humidity. BFX-NLC showed 50% of drug release after 12 h. The in vitro antimicrobial activity demonstrated that the preparation method does not compromise the antimicrobial efficacy of BFX. Additionally, BFX-NLC did not show toxicity in Galleria mellonella larvae. These findings may foster an innovative platform for treating ophthalmic bacterial infections with larger interval between administrations compared to the conventional preparation
- Imprenta:
- Data da defesa: 30.11.2023
- Este periódico é de acesso aberto
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: gold
- Licença: cc-by-nc-sa
-
ABNT
HENOSTROZA, Mirla Anali Bazan. Besifloxacin nanostructured lipid carrier containing for the treatment ophthalmic infections: preparation, physicochemical and biological characterization in vitro and in vivo. 2023. Tese (Doutorado) – Universidade de São Paulo, São Paulo, 2023. Disponível em: https://www.teses.usp.br/teses/disponiveis/9/9139/tde-08032024-162552/. Acesso em: 03 out. 2024. -
APA
Henostroza, M. A. B. (2023). Besifloxacin nanostructured lipid carrier containing for the treatment ophthalmic infections: preparation, physicochemical and biological characterization in vitro and in vivo (Tese (Doutorado). Universidade de São Paulo, São Paulo. Recuperado de https://www.teses.usp.br/teses/disponiveis/9/9139/tde-08032024-162552/ -
NLM
Henostroza MAB. Besifloxacin nanostructured lipid carrier containing for the treatment ophthalmic infections: preparation, physicochemical and biological characterization in vitro and in vivo [Internet]. 2023 ;[citado 2024 out. 03 ] Available from: https://www.teses.usp.br/teses/disponiveis/9/9139/tde-08032024-162552/ -
Vancouver
Henostroza MAB. Besifloxacin nanostructured lipid carrier containing for the treatment ophthalmic infections: preparation, physicochemical and biological characterization in vitro and in vivo [Internet]. 2023 ;[citado 2024 out. 03 ] Available from: https://www.teses.usp.br/teses/disponiveis/9/9139/tde-08032024-162552/ - Nanoemulsão catiônica contendo rifampicina para o tratamento da tuberculose ocular: preparação e caracterização físico-química e microbiológica
- Pesquisadores da USP estudam novas nanoparticulas para tratar infecções bacterianas oculares [Depoimento a Pedro Ferreira]
- Development of a novel in vitro model to study lymphatic uptake of drugs via artificial chylomicrons
- Formulação nanoestruturada para infecção bacteriana ocular
- Biphasic dissolution combined with modified cylinder method—A new promising method for dissolution test in drug-loaded nanoemulsions
- Rifampicin nanocrystals: towards an innovative approach to treat tuberculosis
- Cationic rifampicin nanoemulsion for the treatment of ocular tuberculosis
- Cutting-edge advances in therapy for the posterior segment of the eye: solid lipid nanoparticles and nanostructured lipid carriers
- Antibiotic-loaded lipid-based nanocarrier: a promising strategy to overcome bacterial infection
- Unveiling microtubule dynamics in lung cancer: recent findings and prospects for drug delivery and treatment
Informações sobre o DOI: 10.11606/T.9.2023.tde-08032024-162552 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
